We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
Read MoreHide Full Article
Avanos Medical, Inc. (AVNS - Free Report) reported first-quarter 2022 adjusted earnings per share (EPS) of 26 cents, up 13% year over year. The bottom line surpassed the Zacks Consensus Estimate by 8.3%.
GAAP EPS in the quarter under review was 12 cents against the year-ago quarter’s loss per share of 16 cents.
Revenues
Revenues grossed $197.4 million in the reported quarter, up 9.2% year over year. The metric surpassed the Zacks Consensus Estimate by 0.9%.
Organic revenue growth in constant currency for the quarter was 3%.
The top line was primarily driven by incremental revenues resulting from the acquisition of OrthogenRx, Inc. Strong demand and volume for Digestive health products were also recorded. However, lower demand and volume of respiratory health products offset this.
Q1 Segmental Analysis
Avanos provides a portfolio of innovative product offerings that focuses on Pain Management and Chronic Care.
Pain Management’s net revenues of $78 million surged 30.9% on a year-over-year basis. Excluding the OrthogenRx buyout, the business recorded revenues of $63 million, up by more than 6% compared with the prior-year period.
Chronic Care’s net revenues of $119.4 million declined 1.4% year over year despite strength in Digestive Health. NeoMed neonatal and pediatric feeding solutions grew 32% from continued conversion to ENFit.
Avanos Medical, Inc. Price, Consensus and EPS Surprise
In the quarter under review, Avanos’ gross profit rose 17.4% to $107.2 million. Gross margin expanded 378 basis points (bps) to 54.3%.
Selling and general expenses rose 22.8% to $90.1 million. Research and development expenses declined 6% year over year to $7.8 million. Adjusted operating expenses of $97.9 million increased 19.8% year over year.
Adjusted operating profit totaled $9.3 million, reflecting a 3.1% fall from the prior-year quarter’s level. Adjusted operating margin in the first quarter contracted 60 bps to 4.7%.
Financial Update
The company exited first-quarter 2022 with cash and cash equivalents worth $104.3 million compared with $118.5 million at the end of 2021. Long-term debt at the end of first-quarter 2022 was $254.4 million compared with $130 million at the end of 2021.
Net cash provided by operating activities at the end of first-quarter 2022 totaled $1.8 million compared with net cash used in operating activities of $3.3 million in the prior-year quarter.
In the first quarter of 2022, Avanos repurchased 588,293 shares of its common stock for $19.3 million, thereby completing its repurchases under a board-authorized $30 million repurchase program.
Guidance
Avanos has reiterated its full-year 2022 outlook.
The company continues to expect full-year net sales in the range of $830-$850 million, suggesting organic growth of 3-6%. The Zacks Consensus Estimate for the same currently stands at $841 million.
The company continues to anticipate full-year 2022 adjusted EPS between $1.55 and $1.75. The Zacks Consensus Estimate for the same currently stands at $1.66.
Our Take
Avanos exited the first quarter of 2022 with better-than-expected results. The year-over-year improvement in the overall top and bottom line was impressive. Strength exhibited by Avanos’ core Pain Management segment along with improvements in both Acute pain and Interventional Pain solutions is encouraging. The continued strong demand for Digestive Health products and robust sales of NeoMed are promising. Sustained robust growth for Coolief pain therapy, Game Ready cold and compression therapy systems, and ambIT pumps also raise optimism. Expansion of gross margin bodes well.
Yet, the year-over-year decline in the Chronic Care segment and lower volume in Respiratory Health products are worrying. Supply constraints and raw material shortages impacting Avanos’ business are concerning as well. Contraction in adjusted operating margin remains a woe.
Zacks Rank and Key Picks
Avanos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 13.4%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
Avanos Medical, Inc. (AVNS - Free Report) reported first-quarter 2022 adjusted earnings per share (EPS) of 26 cents, up 13% year over year. The bottom line surpassed the Zacks Consensus Estimate by 8.3%.
GAAP EPS in the quarter under review was 12 cents against the year-ago quarter’s loss per share of 16 cents.
Revenues
Revenues grossed $197.4 million in the reported quarter, up 9.2% year over year. The metric surpassed the Zacks Consensus Estimate by 0.9%.
Organic revenue growth in constant currency for the quarter was 3%.
The top line was primarily driven by incremental revenues resulting from the acquisition of OrthogenRx, Inc. Strong demand and volume for Digestive health products were also recorded. However, lower demand and volume of respiratory health products offset this.
Q1 Segmental Analysis
Avanos provides a portfolio of innovative product offerings that focuses on Pain Management and Chronic Care.
Pain Management’s net revenues of $78 million surged 30.9% on a year-over-year basis. Excluding the OrthogenRx buyout, the business recorded revenues of $63 million, up by more than 6% compared with the prior-year period.
Chronic Care’s net revenues of $119.4 million declined 1.4% year over year despite strength in Digestive Health. NeoMed neonatal and pediatric feeding solutions grew 32% from continued conversion to ENFit.
Avanos Medical, Inc. Price, Consensus and EPS Surprise
Avanos Medical, Inc. price-consensus-eps-surprise-chart | Avanos Medical, Inc. Quote
Margin Analysis
In the quarter under review, Avanos’ gross profit rose 17.4% to $107.2 million. Gross margin expanded 378 basis points (bps) to 54.3%.
Selling and general expenses rose 22.8% to $90.1 million. Research and development expenses declined 6% year over year to $7.8 million. Adjusted operating expenses of $97.9 million increased 19.8% year over year.
Adjusted operating profit totaled $9.3 million, reflecting a 3.1% fall from the prior-year quarter’s level. Adjusted operating margin in the first quarter contracted 60 bps to 4.7%.
Financial Update
The company exited first-quarter 2022 with cash and cash equivalents worth $104.3 million compared with $118.5 million at the end of 2021. Long-term debt at the end of first-quarter 2022 was $254.4 million compared with $130 million at the end of 2021.
Net cash provided by operating activities at the end of first-quarter 2022 totaled $1.8 million compared with net cash used in operating activities of $3.3 million in the prior-year quarter.
In the first quarter of 2022, Avanos repurchased 588,293 shares of its common stock for $19.3 million, thereby completing its repurchases under a board-authorized $30 million repurchase program.
Guidance
Avanos has reiterated its full-year 2022 outlook.
The company continues to expect full-year net sales in the range of $830-$850 million, suggesting organic growth of 3-6%. The Zacks Consensus Estimate for the same currently stands at $841 million.
The company continues to anticipate full-year 2022 adjusted EPS between $1.55 and $1.75. The Zacks Consensus Estimate for the same currently stands at $1.66.
Our Take
Avanos exited the first quarter of 2022 with better-than-expected results. The year-over-year improvement in the overall top and bottom line was impressive. Strength exhibited by Avanos’ core Pain Management segment along with improvements in both Acute pain and Interventional Pain solutions is encouraging. The continued strong demand for Digestive Health products and robust sales of NeoMed are promising. Sustained robust growth for Coolief pain therapy, Game Ready cold and compression therapy systems, and ambIT pumps also raise optimism. Expansion of gross margin bodes well.
Yet, the year-over-year decline in the Chronic Care segment and lower volume in Respiratory Health products are worrying. Supply constraints and raw material shortages impacting Avanos’ business are concerning as well. Contraction in adjusted operating margin remains a woe.
Zacks Rank and Key Picks
Avanos currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 13.4%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which surpassed the Zacks Consensus Estimate of a penny. Revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS’ earnings surpassed estimates in the trailing four quarters, the average surprise being 350.5%.